Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT02869217	TitleStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors	Phase Phase 1	Date Added 2016-08-16	Location Canada	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Cyclophosphamide, Fludarabine, TBI-1301	Tags MSS/ MMRp
NCT ID NCT02888743	TitleDurvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer	Phase Phase 2	Date Added 2016-09-05	Location Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Virginia, United States Wisconsin, United States Canada	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs durvalumab, Tremelimumab	Tags MSS/ MMRp
NCT ID NCT03519412	TitlePembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status	Phase Phase 2	Date Added 2018-05-09	Location Italy	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs pembrolizumab (treatment), temozolomide (induction),, Keytruda, Temodar	Tags MSS/ MMRp
NCT ID NCT02886585	TitlePembrolizumab In Central Nervous System Metastases	Phase Phase 2	Date Added 2016-09-01	Location Massachusetts, United States	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs Pembrolizumab	Tags MSS/ MMRp
NCT ID NCT04963283	TitleStudy of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer	Phase Phase 2	Date Added 2021-07-15	Location Colorado, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Cabozantinib, Nivolumab	Tags MSS/ MMRp
NCT ID NCT02484404	TitlePhase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can…	Phase Phase 1, Phase 2	Date Added 2015-06-29	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Cediranib, durvalumab, Olaparib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03365882	TitleS1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery	Phase Phase 2	Date Added 2017-12-07	Location Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Puerto Rico	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta	Tags MSS/ MMRp
NCT ID NCT02298959	TitleTesting the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	Phase Phase 1	Date Added 2014-11-24	Location Florida, United States Maryland, United States Massachusetts, United States Canada	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Pembrolizumab, Ziv-Aflibercept, Keytruda, Zaltrap	Tags MSS/ MMRp
NCT ID NCT03657641	TitleRegorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2018-09-05	Location California, United States Florida, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Pembrolizumab, Regorafenib, Keytruda, Stivarga	Tags MSS/ MMRp
NCT ID NCT03296137	TitleAdoptive Cell Therapy Across Cancer Diagnoses	Phase Phase 1/Phase 2	Date Added 2017-09-28	Location Denmark	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Autologous tumor-infiltrating lymphocytes, Cyclophosphamide, Fludara, Ipilimumab, Nivolumab, proleukin, Opdivo, Yervoy	Tags MSS/ MMRp

Showing 271 to 280 of 299 entries